Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
US Housing Market House Prices Momentum Analysis - 26th Feb 21
FOMC Minutes Disappoint Gold Bulls - 26th Feb 21
Kiss of Life for Gold - 26th Feb 21
Congress May Increase The Moral Hazard Building In The Stock Market - 26th Feb 21
The “Oil Of The Future” Is Set To Soar In 2021 - 26th Feb 21
The Everything Stock Market Rally Continues - 25th Feb 21
Vaccine inequality: A new beginning or another missed opportunity? - 25th Feb 21
What's Next Move For Silver, Gold? Follow US Treasuries and Commodities To Find Out - 25th Feb 21
Warren Buffett Buys a Copper Stock! - 25th Feb 21
Work From Home Inflationary US House Prices BOOM! - 25th Feb 21
Man Takes First Steps Towards Colonising Mars - Nasa Perseverance Rover in Jezero Crater - 25th Feb 21
Musk, Bezos And Cook Are Rushing To Lock In New Lithium Supply - 25th Feb 21
US Debt and Yield Curve (Spread between 2 year and 10 year US bonds) - 24th Feb 21
Should You Buy a Landrover Discovery Sport in 2021? - 24th Feb 21
US Housing Market 2021 and the Inflation Mega-trend - QE4EVER! - 24th Feb 21
M&A Most Commonly Used Software - 24th Feb 21
Is More Stock Market Correction Needed? - 24th Feb 21
VUZE XR Camera 180 3D VR Example Footage Video Image quality - 24th Feb 21
How to Protect Your Positions From A Stock Market Sell-Off Using Options - 24th Feb 21
Why Isn’t Retail Demand for Silver Pushing Up Prices? - 24th Feb 21
2 Stocks That Could Win Big In The Trillion Dollar Battery War - 24th Feb 21
US Economic Trends - GDP, Inflation and Unemployment Impact on House Prices 2021 - 23rd Feb 21
Why the Sky Is Not Falling in Precious Metals - 23rd Feb 21
7 Things Every Businessman Should Know - 23rd Feb 21
For Stocks, has the “Rational Bubble” Popped? - 23rd Feb 21
Will Biden Overheat the Economy and Gold? - 23rd Feb 21
Precious Metals Under Seige? - 23rd Feb 21
US House Prices Trend Forecast Review - 23rd Feb 21
Lithium Prices Soar As Tesla, Apple And Google Fight For Supply - 23rd Feb 21
Stock Markets Discounting Post Covid Economic Boom - 22nd Feb 21
Economics Is Why Vaccination Is So Hard - 22nd Feb 21
Pivotal Session In Stocks Bull Bear Battle - 22nd Feb 21
Gold’s Downtrend: Is This Just the Beginning? - 22nd Feb 21
The Most Exciting Commodities Play Of 2021? - 22nd Feb 21
How to Test NEW and Used GPU, and Benchmark to Make sure it is Working Properly - 22nd Feb 21
US House Prices Vaccinations Indicator - 21st Feb 21
S&P 500 Correction – No Need to Hold Onto Your Hat - 21st Feb 21
Gold Setting Up Major Bottom So Could We See A Breakout Rally Begin Soon? - 21st Feb 21
Owning Real Assets Amid Surreal Financial Markets - 21st Feb 21
Great Investment Ideas For 2021 - 21st Feb 21
US House Prices Momentum Analysis - 20th Feb 21
The Most Important Chart in Housing Right Now - 20th Feb 21
Gold Is the Ultimate Reserve Asset - 20th Feb 21
Is That the S&P 500 And Gold Correction Finally? - 20th Feb 21
Technical Analysis of EUR/USD - 20th Feb 21
The Stock Market Big Picture - 19th Feb 21
Could Silver "Do a Palladium"? - 19th Feb 21
Three More Reasons We Love To Trade Options! - 19th Feb 21
Here’s What’s Eating Away at Gold - 19th Feb 21
Stock Market March Melt-Up Madness - 19th Feb 21
Land Rover Discovery Sport Extreme Ice and Snow vs Windscreen Wipers Test - 19th Feb 21
Real Reason Why Black and Asian BAME are NOT Getting Vaccinated - NHS Covid-19 Vaccinations - 19th Feb 21
New BNPL Regulations Leave Zilch Leading the Way - 19th Feb 21
Work From Home Inflationary House Prices BOOM! - 18th Feb 21
Why This "Excellent" Stock Market Indicator Should Be on Your Radar Screen Now - 18th Feb 21
The Commodity Cycle - 18th Feb 21
Silver Backwardation and Other Evidence of a Silver Supply Squeeze - 18th Feb 21
Why I’m Avoiding These “Bottle Rocket” Stocks Like GameStop - 18th Feb 21
S&P 500 Correction Delayed Again While Silver Runs - 18th Feb 21
Silver Prices Are About to Explode as Stars are Lining up Like Never Before! - 18th Feb 21
Cannabis, Alternative Agra, Mushrooms, and Cryptos – Everything ALT is HOT - 18th Feb 21
Crypto Mining Craze, How We Mined 6 Bitcoins with a PS4 Gaming Console - 18th Feb 21
Stock Market Trend Forecasts Analysis Review - 17th Feb 21
Vaccine Nationalism Is a Multilateral, Neocolonial Failure - 17th Feb 21
First year of a Stocks bull market, or End of a Bubble? - 17th Feb 21
5 Reasons Why People Prefer to Trade Options Over Stocks - 17th Feb 21
The Gold & Gold Stock Corrections Are Normal - 17th Feb 21
WARNING Oculus Quest 2 Update v25 BROKE My VR Headset! - 17th Feb 21
UK Covid-19 Parks PACKED During Lockdown Despite "Stay at Home" Message - Endcliffe Park Sheffield - 17th Feb 21
How to Invest in ETFs in the UK - 17th Feb 21
Real Reason Why Black and Asian Ethnic minorities are NOT Getting Vaccinated - NHS Covid-19 Vaccinations - 16th Feb 21
Gold / Silver: What This "Large Non-Confirmation" May Mean - 16th Feb 21
Major Optimism for Platinum, Silver, and Copper - 16th Feb 21
S&P 500 Correction Looming, Just as in Gold – Or Not? - 16th Feb 21
Stock Market Last pull-back before intermediate top? - 16th Feb 21
GAMESTOP MANIA BUBBLE BURSTS! Investing Newbs Pump and Dump Roller coaster Ride - 16th Feb 21
Thinking About Starting to Trade This Year? Here Are Some Things to Keep in Mind - 16th Feb 21
US House Prices Real Estate Trend Forecast Review - 15th Feb 21
Will Tesla Charge Gold With Energy? - 15th Feb 21
Feeling the Growing Heat and Tensions in Stocks? - 15th Feb 21
Morgan Stanley Warns Gasoline Industry Is About to Become Totally Worthless - 15th Feb 21
Debts Lift Gold - Precious Metal Prices Will Rise on a Deluge of Red Ink - 15th Feb 21
Platinum Begins Big Breakout Rally - 15th Feb 21
How to Change Car Battery Without Losing Power, Memory, Radio Code Settings - 15th Feb 21
Five reasons why a financial advisor can make a big difference to your small business - 15th Feb 21

Market Oracle FREE Newsletter

FIRST ACCESS to Nadeem Walayat’s Analysis and Trend Forecasts

Big Pharma Will Find Good Hunting Among Early-Stage Biotechs Stocks

Commodities / BioTech Feb 14, 2014 - 09:08 AM GMT

By: TLSReport


Dhesh Govender, manager of the life sciences portfolio for Cedar Lane Enterprises Inc., has the inside track when it comes to identifying the hottest biotech trends. In this interview with The Life Sciences Report, Govender explains why he thinks plenty of upside remains in the life sciences sector, and reveals trade secrets that every investor should consider when building a successful investment strategy.

The Life Sciences Report: Dhesh, you attended the JPMorgan Healthcare Conference and the Biotech Showcase 2014 in San Francisco in mid-January. What takeaway advice do you have for investors looking into the life sciences sector?

Dhesh Govender: This was the 12th JPMorgan Healthcare Conference that I have been privileged to attend. Attendance was up significantly from previous years. Pharma investors were flocking around the reps of early-stage companies, discussing new product launches and partnership possibilities. Conference chatter revolved mostly around mergers and acquisitions (M&A). The takeaway message is that the valuations of early-stage biotech companies are poised to increase significantly, in tandem with a widely expected surge in M&A activity during 2014.

TLSR: Are the great returns that we saw in 2013 going to continue?

DG: In the early-stage small-cap space, there is significant upside to be realized. However, the upside for many large-cap biopharmas will be capped, especially for firms with product launches. We shall closely monitor the new product trajectories, but companies that enjoyed prelaunch valuation bump-ups will be looking to grow their markets. These firms will continue to concentrate on developing preclinical, phase 1-type assets, as well as on building revolutionary tools to help with clinical trials and patient assessment. On the diagnostic side, for example, companies will employ innovative theranostic (integrated therapeutic and diagnostic) methods to identify the right patients for a drug. I anticipate a small-cap rally to occur early on in the year, with activity leveling off in Q3/14. Then small caps will rally again in Q4/14.

TLSR: In San Francisco, you predicted that 18–20 major life science deals are coming down the pike. What is the catalyst for the life sciences rush?

DG: The books are closed for 2013 and investors have to deploy fresh capital. I know of several large funds that are launching as we speak, and these funds are dedicating more than $500 million ($500M) to the life sciences. Interest in the biotech sector is currently similar to that given to information sector technologies in 2001–2002, when there was an absolute flurry of amazing deals. Last year alone, more than $10 billion ($10B) was raised for life science companies. I expect that number to be surpassed in 2014. The challenge for investors, naturally, is to find well-managed companies with great technology coupled to valuations poised for maximum return.

TLSR: At the San Francisco showcase, presenters talked about different kinds of therapy areas and new technologies, including regenerative medicine. What technologies drew your attention as an investor?

DG: New technologies in the oncology and neurology spaces are especially ready to generate premium pricing power in the marketplace. One reason for the expected windfall is that the regulatory agencies are increasingly amenable to authorizing shorter time horizons for oncologic and neurologic product approvals.

The barometer is the U.S. Food and Drug Administration (FDA), as well as federal funding for the National Institutes of Health and National Cancer Institute. Even though funding levels have diminished, changes in how the FDA regulates the approval of new drugs are giving these biotech spaces a boost. With its new leadership going great guns, the FDA is now very amenable to working with the needs of new technology companies. We expect that to continue.

In fact, the oncology and neurology sectors contain a goodly number of undervalued companies with upcoming catalysts that have not yet appeared on the status quo radars. I expect to see an influx of initial public offerings for new companies in regenerative medicine and with cell-based therapies for oncology, neurology, and immunology. These in-the-wings product ripenings bode well for good hunting by big pharma.

TLSR: Can you talk about any of the companies you are following in these arenas?

DG: In 2013, Novartis AG (NVS:NYSE) made a very lucrative deal with the University of Pennsylvania to support Carl Junes' work on CD19 for chronic lymphocytic leukemia (CLL). That is a template for the future.Bristol-Myers Squibb Co. (BMY:NYSE) and Merck & Co. Inc. (MRK:NYSE) are taking advantage of the excellent data presented on their PD-1 and PD-L1 antibodies at the American Society for Clinical Oncology in June. Investors in the checkpoint inhibition space will be very well positioned for developments during 2014, I must say.

TLSR: During 2014, will the trend for small life science companies be about solidifying partnerships with big pharma or about positioning for acquisitions?

DG: The opportunities for smaller companies to partner and to make deals is ripe, because big pharma has to enter early to realize substantial value. Smart companies were represented by top management at the Biotech Showcase in San Francisco. Investors want to talk directly to the CEOs and scientists at early-stage companies. I had dinner with a Roche Holding AG (RHHBY:OTCQX) executive during the conference. Roche sent about 150 of its upper-level people to the conference to look at smaller companies and their innovative technologies, and to talk turkey.

TLSR: Is there competition between the juniors for access to the deep pockets of big pharma? What strategies are used to garner such attention?

DG: Data is the currency for early-stage companies. They can demonstrate value as a partner for a large pharma if they have certain proprietary tools and, more important, if they have a target or a product candidate that fits nicely into the large biopharma's existing pipeline—or that can flow in combination with an already approved drug. For example, new vaccines that can be combined with current therapy are hot.

Remember too that pharma is a global marketplace. U.S.-domiciled firms with attractive intellectual properties are focusing on the global market, and non-U.S. firms are looking toward the U.S. markets.

TLSR: Let's talk about the pace of innovation, particularly in genomic sequencing, which is accelerating. Is that going to bring down the cost of development for smaller biotech companies and open up access to banking and investment capital?

DG: Innovation in the cost of genomic sequencing is leveling the playing field. For example, the cost of running a trial using the whole genome sequencing services offered by Illumina Inc. (ILMN:NASDAQ) is now less than $1,000. That means smaller biotechs can compete with large pharma in product development and testing. Traditionally, sequencing costs were tens of thousands of dollars per test.

We all know Moore's law, from the technology sector. That trend will continue; paying even less than $1,000 for genomic sequencing is a sweet spot that can be touched. Lowering these costs means more people will be able to pay for access to these new technologies. That will force large pharma to increasingly collaborate with smaller firms at the edge of innovation.

TLSR: Can you provide specific examples of companies poised to take advantage of M&A, partnerships, or new innovations? Are you adjusting your portfolio to take advantage of these trends?

DG: Without getting into trouble with the compliance department at my firm, Cedar Lane Enterprises, I can suggest that checkpoint inhibition is a very hot topic in mergers and acquisitions. We are a hedge fund, and we are constantly looking at strategies and catalysts on the derivative side, as well as the long-short side, to maximize returns. Traditionally, we have observed that pending deals that have not been done by the end of the year are usually done toward the beginning of the new year. We expect a lot more news flow in this sector in terms of M&A, and we will position our portfolio to take advantage of that, especially on the derivative side, during April, May and, possibly, June.

TLSR: Are there any companies with interesting technologies or catalysts that you'd like to talk about?

DG: Sorrento Therapeutics Inc. (SRNE:NASDAQ) has an antibody drug conjugate platform that is blossoming into a full-fledged pipeline project. The driver of Sorrento's lead program is a nanoformulated paclitaxel (Taxol). The company will commence its pivotal first patient trials with this therapy in the U.S. any day now.

With a $213M market cap and a potential launch in two years, Sorrento is tremendously undervalued. Sorrento was started up by the team that launched and developed Abraxane, also a nanoformulated paclitaxel, which was acquired by Celgene Corp. (CELG:NASDAQ). At the JPMorgan conference we heard from Celgene's CEO; Abraxane guided $2B in peak sales in 2013 and should add another $1B in sales this year. Success breeds success!

TLSR: Thanks for your time, Dhesh.

DG: Cheers.

Dhesh S.K. Govender is a portfolio manager for healthcare and life sciences with the Cedar Lane Fund, a division of New York-based Cedar Lane Enterprises.

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Tracy Salcedo-Chourré conducted this interview for The Life Sciences Report and provides services toThe Life Sciences Report as an employee. She or her family own shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the interview are sponsors of The Life Sciences Report: None. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.
3) Dhesh Govender: I or my family own shares of the following companies mentioned in this interview: Sorrento Therapeutics Inc. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: Sorrento Therapeutics Inc. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
4) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts' statements without their consent.
5) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer.
6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Life Sciences Report is Copyright © 2014 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part..

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110
Petaluma, CA 94952

Tel.: (707) 981-8204
Fax: (707) 981-8998

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules